Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
June 11, 2024 09:00 ET
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
June 10, 2024 09:00 ET
|
Longeveron
Longeveron to Present at the Emerging Growth Virtual Conference
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
June 03, 2024 09:00 ET
|
Longeveron
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Announces Board of Directors Planned Transitions
May 10, 2024 16:05 ET
|
Longeveron
Longeveron announces planned transitions on its Board of Directors.
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
May 02, 2024 08:03 ET
|
Longeveron
Longeveron to report Q1 2024 financial results on May 14, 2024.
Longeveron to Present at the Planet MicroCap Showcase
April 25, 2024 16:05 ET
|
Longeveron
Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
April 18, 2024 16:05 ET
|
Longeveron
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron Announces Closing of $5.2 Million Public Offering
April 11, 2024 17:17 ET
|
Longeveron
Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.